Lingshi Tan,
PhD

Dr. Tan is Chairman and Chief Executive Officer of dMed Company Limited, a China-based contract research organization that provides comprehensive services to biopharmaceutical and medical device companies in China and globally, including advising customers on all aspects of clinical development plan, regulatory strategy, and approval processes, as well as full clinical trial support.

Prior to founding dMed, Dr. Tan was Pfizer’s Vice President of Worldwide Development Operations and Chairman and General Manager of Pfizer (China) Research & Development Co., Ltd. After nine years of working at Pfizer’s New York headquarters, he made a compelling business case for Pfizer to invest in research and development in China and was assigned to Shanghai to establish the Pfizer (China) Research & Development Co., Ltd in 2005. As the Pfizer (China) Research & Development Co., Ltd., celebrated its five-year anniversary in October 2010, Dr. Tan’s team made another strategic move — opening the second China research and development center for Pfizer in the central city of Wuhan. Today, the Pfizer (China) Research & Development Co., Ltd. (Shanghai, Wuhan, Beijing) has grown to an organization of more than 1,000 professionals. In addition to supporting clinical development in China, the Pfizer (China) Research & Development Co., Ltd. has become an integral part of Pfizer’s global research and development network, focusing on clinical development, safety, regulatory, and medical and compliance functions.

Before returning to China to assume this role, Dr. Tan served as Pfizer’s Head of Global Biometrics for the Japan/Asia/Africa/Mid-East/Latin America region since 2001. Dr. Tan joined Pfizer in 1996, following biostatistical positions at Children's Hospital of Pittsburgh and Schering-Plough Research Institute in New Jersey.

In 2009, Dr. Tan co-founded a novel industry-academic collaboration with Fudan University and created the first formal graduate program in Clinical Data Management and Statistical Programming in China. Dr. Tan is also a council member for Peking University’s Pharmaceutical Information and Engineering Research Center, and the inaugural Chair of the Research and Development Heads Working Group of Research and Development-based Pharmaceutical Association Committee in China. Dr. Tan received his PhD in Biostatistics and a Masters of Arts in Applied Mathematics, both from the University of Pittsburgh.